Your browser is no longer supported. Please, upgrade your browser.
Settings
MDVN Medivation, Inc. daily Stock Chart
MDVN [NASD]
Medivation, Inc.
Index- P/E- EPS (ttm)-1.17 Insider Own1.20% Shs Outstand165.93M Perf Week0.67%
Market Cap13.51B Forward P/E37.34 EPS next Y2.18 Insider Trans-0.64% Shs Float163.73M Perf Month1.36%
Income-177.10M PEG- EPS next Q0.38 Inst Own91.00% Short Float1.98% Perf Quarter40.92%
Sales1.03B P/S13.16 EPS this Y-11.10% Inst Trans-1.44% Short Ratio0.75 Perf Half Y117.81%
Book/sh3.24 P/B25.14 EPS next Y72.27% ROA-13.00% Target Price77.15 Perf Year104.47%
Cash/sh1.97 P/C41.30 EPS next 5Y37.68% ROE-23.80% 52W Range26.41 - 81.48 Perf YTD68.47%
Dividend- P/FCF44.41 EPS past 5Y50.90% ROI27.10% 52W High-0.05% Beta0.63
Dividend %- Quick Ratio4.30 Sales past 5Y72.10% Gross Margin- 52W Low208.37% ATR0.55
Employees628 Current Ratio4.30 Sales Q/Q17.40% Oper. Margin-26.30% RSI (14)85.63 Volatility0.11% 0.23%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin-17.20% Rel Volume1.70 Prev Close81.44
ShortableYes LT Debt/Eq0.00 EarningsNov 03 AMC Payout- Avg Volume4.29M Price81.44
Recom2.80 SMA200.59% SMA5011.96% SMA20050.90% Volume0 Change0.00%
Aug-23-16Downgrade Stifel Buy → Hold
Aug-23-16Downgrade Maxim Group Buy → Hold $76 → $81.50
Aug-23-16Downgrade Credit Suisse Outperform → Neutral
Aug-22-16Downgrade SunTrust Buy → Neutral
Aug-22-16Downgrade Citigroup Buy → Neutral
Aug-10-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jul-12-16Reiterated Wedbush Outperform $63 → $66
May-06-16Upgrade Citigroup Neutral → Buy
May-06-16Reiterated Barclays Overweight $48 → $70
May-05-16Reiterated Maxim Group Buy $47 → $76
May-02-16Reiterated Stifel Buy $52 → $66
May-02-16Reiterated Jefferies Hold $39 → $52
Apr-29-16Reiterated Wedbush Outperform $47 → $59
Apr-06-16Initiated Sun Trust Rbsn Humphrey Buy $56
Mar-31-16Reiterated Credit Suisse Outperform $48 → $49
Mar-30-16Initiated Goldman Neutral
Feb-19-16Initiated BofA/Merrill Buy
Feb-01-16Reiterated Wedbush Outperform $59 → $47
Jan-27-16Downgrade Canaccord Genuity Buy → Hold $90 → $45
Jan-21-16Initiated Credit Suisse Outperform
Sep-29-16 05:04PM  A Look at the Pfizer-Medivation Deal
Sep-28-16 09:03AM  MEDIVATION, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisition or Dis
08:50AM  Pfizer Completes Acquisition of Medivation Business Wire
06:00AM  Medivation Highlights New Data From Differentiated Oncology Portfolio at ESMO 2016 Marketwired
Sep-27-16 09:12AM  Blog Coverage US Pharma Giant Pfizer to Whole as one Complete Unit
Sep-26-16 04:30PM  Unexpected Twist: Pfizer Scraps Breakup Following Dead Allergen Merger
02:48PM  These Investors Are Glad Pfizer Has Decided Not to Split at Barrons.com
12:17PM  Read Scraps Pfizer Break-Up as Megadeals Escape Its Grasp
11:24AM  Pfizer: Split Decision at Barrons.com
07:00AM  Billionaire James Dinans York Capital Initiated Stakes in These Companies at Insider Monkey
Sep-23-16 08:30AM  Pfizer Announces Expiration of HSR Waiting Period For Proposed Acquisition of Medivation Business Wire
Sep-22-16 09:56AM  New Setback for Sanofi's Lantus Increases Need for M&A
Sep-20-16 02:49PM  How Ionis Pharmaceuticals Valuation Compares to Its Peers
Sep-16-16 09:30AM  Zacks.com featured highlights: PTC, Capital Senior Living, ZELTIQ Aesthetics, Conns and Medivation
Sep-15-16 03:00PM  The Cannabis-Based Biotech Sector's Best Buyout Candidates at Forbes
08:00AM  PARP Wars: Biotech M&A's New Hope at Bloomberg
Sep-14-16 08:42AM  Why Pfizer's Stock Is a Big Gamble Right Now at Motley Fool
08:20AM  Key FDA Decisions and Trial Results Coming in the Next 2 Months at 24/7 Wall St.
Sep-12-16 11:49AM  This Forbes 'Most Innovative' Growth Stock Remains Near Buy Point
10:13AM  2 Biotech Stocks that Turned $8,000 into over $250,000 at Motley Fool
09:55AM  Best and worst from Delivering Alpha 2015
08:35AM  5 Questions and Answers Take a Measure of Biotech Investor Sentiment
Sep-09-16 04:33PM  [$$] Would Gilead Pick Up Tesaro's PARP? at Barrons.com
02:08PM  Faruqi & Faruqi, LLP Announces Filing of a Class Action Lawsuit Against Medivation, Inc. PR Newswire
10:25AM  Medivation (MDVN) Scales New 52-Week High on Pfizer Deal
Sep-08-16 05:57PM  Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Medivation, Inc. (MDVN) GlobeNewswire
04:49PM  Clovis Oncology Up As FDA Skips Review Panel For New Drug
01:21PM  Why Clovis Oncology Inc. Is Soaring Today at Motley Fool
01:08PM  Is Pfizer About to Slash Its Dividend? at Motley Fool
08:05AM  Key FDA Decisions and Trial Results Expected in October at 24/7 Wall St.
Sep-06-16 04:48PM  MEDIVATION SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Medivation, Inc. (MDVN) Over the Proposed Sale of the Company to Pfizer Inc. PR Newswire
04:00PM  3 Hottest Cancer Biotech Acquisition Targets After Medivation at Forbes
Sep-02-16 04:32PM  MEDIVATION, INC. Files SEC form 8-K, Change in Directors or Principal Officers
11:10AM  SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of Medivation, Inc. Business Wire
10:12AM  ETFs with exposure to Medivation, Inc. : September 2, 2016
08:04AM  An Overview of Pfizers Oncology Business
Sep-01-16 01:53PM  Biotech Stocks: Look At Those Takeover Premiums! at Barrons.com
01:04AM  [$$] Bidding War for Medivation Is Good News for Biotech at The Wall Street Journal
Aug-31-16 04:49PM  Is Pfizer Paying Too Much to Buy Medivation? at Motley Fool
01:28PM  [$$] Bidding War for Medivation Is Good News for Biotech at The Wall Street Journal
12:43PM  Medivation Proxy Shows Pfizer Battled Four Bidders to Seal a Deal
08:35AM  What's Up With Mylan's EpiPen Pricing? at Motley Fool
Aug-29-16 11:21AM  In Wake Of Medivation Deal, Argus Thinks Pfizer's Existing Business Is Underrated
10:05AM  Whats the Story behind the Pfizer-Medivation Deal?
09:44AM  Why Pfizer Remains Attractively Valued With Medivation at Forbes
Aug-28-16 06:49AM  3 Stocks Up Over 1,000% in the Past 5 Years at Motley Fool
Aug-27-16 06:36PM  Here Are All The Big Biotech Mergers In 2016
12:50AM  Huge Jumps In Hedge Fund Popularity For These 5 Healthcare Stocks at Insider Monkey
12:01AM  [$$] U.K. Diners Are Nuts for Online Takeout at Barrons.com
Aug-26-16 10:05AM  What Should We Expect from BioMarins Kuvan in 2016?
09:24AM  Dow 30 Stock Roundup: Pfizer's Big Buy, Boeing's Big Win
09:20AM  3 Top Stocks For Retirees at Motley Fool
08:02AM  Game On for Pfizer With $14 Billion Medivation Buyout (or, Why Pfizer's Buyout of Medivation Could Be a Smart Move) at Motley Fool
Aug-25-16 10:00PM  INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Medivation, Inc. And Encourages Shareholders To Contact The Firm For Additional Information Business Wire
03:18PM  Pfizer (PFE) Stock Earnings Estimates Raised at Jefferies on $14 Billion Medivation Deal
02:50PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding Whether the Sale of Medivation, Inc. for $81.50 Per Share is Fair to Shareholders Business Wire
08:31AM  How Mylan And Pfizer Could Cause A Major Biotech Backlash at Forbes
Aug-24-16 04:50PM  Biotech Stocks Seesaw As M&A Hopes Meet New Pricing Fears
03:41PM  Dear Pfizer, Stop Overpaying for Acquisitions! at Motley Fool
02:42PM  Pfizer's $1.5 Billion Antibiotics Buy: Strategic Long-Term Planning Or Pre-Split Prep?
02:09PM  Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
11:17AM  [$$] Smaller Biotech Buyout Targets After Medivation at Barrons.com
11:04AM  Medivation: The Latest Analyst Recommendations
10:56AM  Risk Arbitrage Trading Strategies
10:00AM  Write A Prescription For More Pharma M&A With This ETF
09:04AM  How Xtandi Fueled Big Pharmaceutical Interest in Medivation
09:04AM  Why Pfizer's Latest Deal Could Send Its Shares Soaring
08:00AM  Forget About That Pfizer Mega-Merger at Bloomberg
Aug-23-16 08:43PM  SHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of Medivation, Inc. -MDVN PR Newswire
03:29PM  INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding Whether the Sale of Medivation, Inc. to Pfizer Inc. is Fair to Shareholders Business Wire
02:39PM  Pfizer & Medivation: A Big Win Like Gilead-Pharmasset or a Big Bust Like Bristol-Inhibitex? at Barrons.com
10:10AM  Stock Market News for August 23, 2016
09:44AM  4 Biotech Buyout Targets for Gilead, Sanofi After Medivation Miss at Barrons.com
09:30AM  Deals of the Day: Apple Gets a Gliimpse, Pfizer's Steep Price at The Wall Street Journal
09:04AM  Pfizers Medivation Acquisition: What You Need to Know
08:58AM  Pfizer Has Had A Busy M&A Year...Or Has It?
08:47AM  Medivation (MDVN) Stock Downgraded After Pfizer Deal
07:01AM  What Pfizer Gets in Its $14 Billion Medivation Deal at Motley Fool
06:51AM  Medivation downgraded by Credit Suisse, Stifel and Maxim Group
04:50AM  Pfizer to Buy Medivation for $14B, Boost Cancer Franchise (revised)
02:52AM  Pfizer acquires biotech firm Medivation for $14 billion
12:23AM  PRESS DIGEST- New York Times business news - Aug 23
12:09AM  [$$] Pfizer to Buy Medivation for $14 Billion at The Wall Street Journal
12:07AM  [$$] Medivation Ovation: Pfizer Pays the Price for Growth at The Wall Street Journal
Aug-22-16 11:36PM  M&A is key to Pfizer's sales growth: Strategist +19.74%
11:05PM  The $150 million winner and the losers in Pfizer's $14 billion takeout of Medivation at bizjournals.com
08:56PM  [$$] Pfizer Adds Key Cancer Drug With $14 Billion Medivation Deal at The Wall Street Journal
08:04PM  PRESS DIGEST- British Business - August 23 Reuters
07:19PM  Pfizer-Medivation cash deal is hard to justify: Analyst
07:02PM  Cramer: Forget biotech! THIS is the next red-hot takeover group at CNBC
07:01PM  Cramer: A Bunch of Semis Are Ripe for the Picking
06:54PM  Stocks Calm As Crude Plunges; Busy Day For Medical Sector
06:51PM  Pfizer Acquires Medivation
06:39PM  Pfizer boosts cancer drug roster with $14 billion Medivation deal Reuters
05:50PM  SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Medivation, Inc. And Encourages Investors To Contact The Firm For Additional Information Business Wire
05:32PM  In possible $14 billion ending, Medivation goes back to early days at bizjournals.com
05:25PM  Biotech's next big deal?
05:06PM  Pfizer (PFE) Bought Medivation (MDVN), but is it a Good Deal?
05:04PM  What Happened in the Stock Market Today at Motley Fool
04:43PM  U.S. Stocks Ease as Markets Watch Oil, Fed at The Wall Street Journal
Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of medical therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (CRPC) patients. The company also develops Enzalutamide, which is in phase III clinical trials for the treatment of non-metastatic CRPC, and metastatic and non-metastatic hormone sensitive prostate cancer; and phase II clinical trials for the treatment of hepatocellular carcinoma, androgen receptor positive (AR+) triple negative breast cancer, estrogen receptor positive or progesterone receptor positive and human epidermal growth factor receptor 2 (HER2) normal breast cancer, and AR+ HER2 amplified breast cancer. In addition, it develops Talazoparib, which is in phase II clinical trials for treatment of germline mutated HER2 normal breast cancer; Pidilizumab that is in phase II clinical trials for the treatment of relapsed or refractory diffuse large B-cell lymphoma; and MDV4463, which is in phase I clinical trials for the treatment of nonalcoholic steatohepatitis. The company has collaboration agreement with Astellas Pharma, Inc. for the development, manufacture, and commercialization of XTANDI; and license and manufacturing, and supply agreement with CureTech, Ltd. for the development, manufacture, and commercialization of biologic molecules. Medivation, Inc. is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BLICKENSTAFF KIM DDirectorSep 21Option Exercise2.2125,50056,35543,242Sep 26 04:47 PM
Hirmand MohammadInterim Chief Medical OfficerSep 15Option Exercise4.4717,56078,52357,523Sep 19 04:50 PM
Hung DavidPresident and CEOSep 15Option Exercise4.8830,754149,9811,564,377Sep 19 04:49 PM
Powell Andrew Kenneth WilliamSVP, General Counsel & Crp SecJun 06Sale60.422,578155,76328,517Jun 06 08:10 PM
Bierly RickCFO (former)May 06Sale60.126,315379,63728,744May 09 05:35 PM
Bierly RickCFO (former)May 05Sale59.204,025238,28035,059May 09 05:35 PM
Svoronos DawnDirectorMar 14Sale38.906,000233,40018,234Mar 16 05:06 PM
Hirmand MohammadInterim Chief Medical OfficerMar 04Sale41.101,52562,68539,342Mar 07 08:44 PM
Bierly RickChief Financial OfficerMar 04Sale40.002,998119,92039,084Mar 07 08:43 PM
Hung DavidPresident and CEOFeb 04Sale31.186,350197,9931,504,654Feb 05 07:05 PM
Machado Clarence PatrickDirectorJan 19Option Exercise3.3775,000252,525141,156Jan 21 05:45 PM
Machado Clarence PatrickDirectorJan 19Sale37.3475,0002,800,56266,156Jan 21 05:45 PM
Lobacki Joseph MChief Commercial OfficerJan 04Sale46.503,065142,52319,365Jan 05 06:14 PM
VERNON W ANTHONYDirectorDec 14Buy40.6915,000610,35028,704Dec 16 05:40 PM
Hung DavidPresident and CEODec 03Sale43.1010,950471,9661,511,004Dec 04 04:36 PM
Hirmand MohammadInterim Chief Medical OfficerDec 03Sale43.401,07546,65531,113Dec 04 04:35 PM
Hirmand MohammadInterim Chief Medical OfficerNov 09Sale41.912329,72232,188Nov 12 06:46 PM